Pork with Alpha-Gal for Alpha-Gal Syndrome
Trial Summary
What is the purpose of this trial?
This is a double-blind, crossover food challenge study using pork with and without α-gal in patients with a clinical diagnosis of gastrointestinal (GI)- α-gal allergy, and to investigate the pathophysiology underlying their symptoms.
Will I have to stop taking my current medications?
You will need to stop taking nonsteroidal anti-inflammatory medications, leukotriene modifiers, and steroids 14 days before the challenge. If you are using systemic steroids, you must stop 28 days before the food challenge. The protocol does not specify other medications, so please consult with the study team for more details.
What makes the treatment with pork containing alpha-gal unique for Alpha-Gal Syndrome?
Research Team
Sarah McGill, MD
Principal Investigator
University of North Carolina, Chapel Hill
Eligibility Criteria
This trial is for individuals with a clinical diagnosis of GI-alpha-gal allergy, which can cause symptoms like diarrhea, irritable bowel syndrome, abdominal pain, and vomiting. Specific eligibility criteria are not provided.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Food Challenge Phase 1
Participants undergo a double-blind food challenge with pork meat containing alpha-gal sugar
Washout Period
A washout period of at least 10 days between food challenges
Food Challenge Phase 2
Participants undergo a double-blind food challenge with pork meat without alpha-gal sugar
Follow-up
Participants are monitored for safety and effectiveness after the food challenges
Treatment Details
Interventions
- Ground pork containing alpha-gal (Other)
- Pork meat not containing alpha-gal (Other)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of North Carolina, Chapel Hill
Lead Sponsor
Dr. Peggy P. McNaull
University of North Carolina, Chapel Hill
Chief Medical Officer
MD from Louisiana State University School of Medicine
Dr. Lynne Fiscus
University of North Carolina, Chapel Hill
Chief Executive Officer since 2020
MD from Georgetown University, MPH from UNC
Revivicor, Inc
Collaborator